Cargando…
Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients
Introduction. Antibiotic treatment regimens against Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients often include aminoglycoside antibiotics that may cause chronic renal failure after repeated courses. Aminoaciduria is an early marker of acute aminoglycoside-induced renal tubu...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241496/ https://www.ncbi.nlm.nih.gov/pubmed/28133546 http://dx.doi.org/10.1155/2017/2602653 |
_version_ | 1782496193273659392 |
---|---|
author | Stehling, Florian Büscher, Rainer Grosse-Onnebrink, Jörg Hoyer, Peter F. Mellies, Uwe |
author_facet | Stehling, Florian Büscher, Rainer Grosse-Onnebrink, Jörg Hoyer, Peter F. Mellies, Uwe |
author_sort | Stehling, Florian |
collection | PubMed |
description | Introduction. Antibiotic treatment regimens against Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients often include aminoglycoside antibiotics that may cause chronic renal failure after repeated courses. Aminoaciduria is an early marker of acute aminoglycoside-induced renal tubular dysfunction. We hypothesized that urinary amino acid reabsorption is decreased after repeated once-daily tobramycin therapies. Methods. In this prospective cross-sectional study creatinine clearance was estimated by the Schwartz and the Cockcroft-Gault formula. Tubular amino acid reabsorption was determined by ion exchange chromatography in 46 patients with CF who received multiple tobramycin courses (6.3 ± 10.1 (1–57)) in a once-daily dosing regimen and 10 who did not. Results. Estimated creatinine clearance employing the Cockcroft-Gault was mildly reduced in 17/46 (37%) of the patients who received tobramycin and 5/10 (50%) of the patients who did not but in none using the Schwartz formula. No association with lifetime tobramycin courses was found. Tubular amino acid reabsorption was not influenced by the amount of once-daily tobramycin courses. Conclusion. Clinically not significant reduction of eCCL occurred in a minority of CF patients. However, chronic tubular dysfunction was not present in patients with CF repeatedly treated with tobramycin in the once-daily dosing scheme. |
format | Online Article Text |
id | pubmed-5241496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-52414962017-01-29 Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients Stehling, Florian Büscher, Rainer Grosse-Onnebrink, Jörg Hoyer, Peter F. Mellies, Uwe Pulm Med Clinical Study Introduction. Antibiotic treatment regimens against Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients often include aminoglycoside antibiotics that may cause chronic renal failure after repeated courses. Aminoaciduria is an early marker of acute aminoglycoside-induced renal tubular dysfunction. We hypothesized that urinary amino acid reabsorption is decreased after repeated once-daily tobramycin therapies. Methods. In this prospective cross-sectional study creatinine clearance was estimated by the Schwartz and the Cockcroft-Gault formula. Tubular amino acid reabsorption was determined by ion exchange chromatography in 46 patients with CF who received multiple tobramycin courses (6.3 ± 10.1 (1–57)) in a once-daily dosing regimen and 10 who did not. Results. Estimated creatinine clearance employing the Cockcroft-Gault was mildly reduced in 17/46 (37%) of the patients who received tobramycin and 5/10 (50%) of the patients who did not but in none using the Schwartz formula. No association with lifetime tobramycin courses was found. Tubular amino acid reabsorption was not influenced by the amount of once-daily tobramycin courses. Conclusion. Clinically not significant reduction of eCCL occurred in a minority of CF patients. However, chronic tubular dysfunction was not present in patients with CF repeatedly treated with tobramycin in the once-daily dosing scheme. Hindawi Publishing Corporation 2017 2017-01-04 /pmc/articles/PMC5241496/ /pubmed/28133546 http://dx.doi.org/10.1155/2017/2602653 Text en Copyright © 2017 Florian Stehling et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Stehling, Florian Büscher, Rainer Grosse-Onnebrink, Jörg Hoyer, Peter F. Mellies, Uwe Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients |
title | Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients |
title_full | Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients |
title_fullStr | Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients |
title_full_unstemmed | Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients |
title_short | Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients |
title_sort | glomerular and tubular renal function after repeated once-daily tobramycin courses in cystic fibrosis patients |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241496/ https://www.ncbi.nlm.nih.gov/pubmed/28133546 http://dx.doi.org/10.1155/2017/2602653 |
work_keys_str_mv | AT stehlingflorian glomerularandtubularrenalfunctionafterrepeatedoncedailytobramycincoursesincysticfibrosispatients AT buscherrainer glomerularandtubularrenalfunctionafterrepeatedoncedailytobramycincoursesincysticfibrosispatients AT grosseonnebrinkjorg glomerularandtubularrenalfunctionafterrepeatedoncedailytobramycincoursesincysticfibrosispatients AT hoyerpeterf glomerularandtubularrenalfunctionafterrepeatedoncedailytobramycincoursesincysticfibrosispatients AT melliesuwe glomerularandtubularrenalfunctionafterrepeatedoncedailytobramycincoursesincysticfibrosispatients |